Understanding OUR Cytokine-Based Immunotherapy Candidates Our Commitment extends to advancing a robust portfolio of programs geared toward expanding the horizons of cytokine-based immunotherapy, especially for cancers where therapy choices remain limited. Use the links below to learn much more about our portfolio of cytokine-based immunotherapy candidates. Discover Our Pipeline https://financefeeds.com/finalto-group-parts-ways-with-long-serving-ceo-matthew-maloney/